Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...

But quality-of-life findings should be considered alongside DFS benefit, says researcher ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...

Phase II data suggest fewer GI adverse effects when given a sequence of biologics ...

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Find out how immunotherapy can improve cancer treatment outcomes and the systemic barriers limiting its widespread use.

Children with food allergy who used omalizumab plus oral immunotherapy vs. omalizumab alone had similar rates of allergen ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...